Pfizer: 3.8% of trial participants felt fatigue after 2nd jab

Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.

Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The U.S. drugmaker said 2% of participants experienced headaches after the second shot.

https://www.reuters.com/article/us-health-coronavirus-vaccines-safety/pfizer-says-analysis-shows-3-8-of-participants-experienced-fatigue-idUSKBN27Y1XM